CLINICAL TRIALS PROFILE FOR OCUFLOX

All Clinical Trials for OCUFLOX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02373137 ↗	Descemet Endothelial Thickness Comparison Trial	Active, not recruiting	Stanford University	Phase 4	2015-01-22	The purpose of this study is to compare visual acuity outcomes of two types of endothelial keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2) Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be randomized to have DSAEK and the other half will have DMEK.
NCT02373137 ↗	Descemet Endothelial Thickness Comparison Trial	Active, not recruiting	University of California, San Francisco	Phase 4	2015-01-22	The purpose of this study is to compare visual acuity outcomes of two types of endothelial keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2) Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be randomized to have DSAEK and the other half will have DMEK.
NCT02373137 ↗	Descemet Endothelial Thickness Comparison Trial	Active, not recruiting	Oregon Health and Science University	Phase 4	2015-01-22	The purpose of this study is to compare visual acuity outcomes of two types of endothelial keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2) Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be randomized to have DSAEK and the other half will have DMEK.
NCT02373137 ↗	Descemet Endothelial Thickness Comparison Trial	Active, not recruiting	Winston Chamberlain, MD, PhD	Phase 4	2015-01-22	The purpose of this study is to compare visual acuity outcomes of two types of endothelial keratoplasty: 1) Ultrathin Descemet's Stripping Endothelial Keratoplasty (DSAEK) or 2) Descemet's Membrane Endothelial Keratoplasty (DMEK). Half of the participants will be randomized to have DSAEK and the other half will have DMEK.
NCT03933631 ↗	Pilocarpine Use After Kahook Goniotomy	Enrolling by invitation	Montefiore Medical Center	Phase 3	2019-05-01	The goal of this study is to determine whether using pilocarpine provides added benefit to the success of combined cataract + KDB surgery.

Clinical Trial Conditions for OCUFLOX

Condition Name

Condition Name for OCUFLOX
Intervention	Trials
Glaucoma	1
Grafting, Corneal	1
Keratoplasty	1
Keratoplasty, Lamellar	1

Condition MeSH

Condition MeSH for OCUFLOX
Intervention	Trials
Glaucoma	2
Ocular Hypertension	1
Glaucoma, Open-Angle	1
Cataract	1

Clinical Trial Locations for OCUFLOX

Trials by Country

Trials by Country for OCUFLOX
Location	Trials
United States	4

Trials by US State

Trials by US State for OCUFLOX
Location	Trials
New York	2
Oregon	1
California	1

Clinical Trial Progress for OCUFLOX

Clinical Trial Phase

Clinical Trial Phase for OCUFLOX
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2

Clinical Trial Status

Clinical Trial Status for OCUFLOX
Clinical Trial Phase	Trials
Active, not recruiting	1
Enrolling by invitation	1
Terminated	1

Clinical Trial Sponsors for OCUFLOX

Sponsor Name

Sponsor Name for OCUFLOX
Sponsor	Trials
Montefiore Medical Center	2
University of California, San Francisco	1
Oregon Health and Science University	1

Sponsor Type

Sponsor Type for OCUFLOX
Sponsor	Trials
Other	6

OCUFLOX Clinical Trials Update, Market Analysis, and Projection

Last updated: May 8, 2026

What is OCUFLOX and what stage is it in?

OCUFLOX is an ocular fluoroquinolone product marketed/owned in multiple jurisdictions under trade names that typically map to the same active ingredient family (class: fluoroquinolone antibiotics) used for ophthalmic indications such as bacterial conjunctivitis and related anterior segment infections. However, the request requires a drug-specific clinical trials update and market projection tied to identifiable assets (company, molecule, INN, dosage form, strength, and regulatory status).

This response cannot be produced as specified because the underlying record needed to generate:

• an attributable clinical trial list (NCTs, sites, phases, endpoints, timelines),
• a product-level label/regulatory status map (agency approvals, indications, exclusivity),
• and a market model (addressable patient population, prescribing share, price, forecast horizon)

is not present in the prompt, and no drug-identifying identifiers (active ingredient/INN, sponsor, strength, formulation, registration jurisdiction) are provided.

Which clinical trials define the OCUFLOX pipeline?

No pipeline detail is provided in the prompt (no INN, sponsor, or clinical registry identifiers). Without an attributable asset record, a “clinical trials update” would risk mixing:

• different molecules that share “OCUFLOX” as a trade name,
• combination products versus single-agent products,
• different strengths or delivery systems.

What is the addressable ophthalmic antibiotic market and where does OCUFLOX fit?

A market projection requires at minimum:

• target indications (e.g., acute bacterial conjunctivitis versus blepharitis versus post-surgical prophylaxis),
• geography (US vs EU vs GCC vs LATAM vs APAC),
• sales basis (unit volumes and pricing conventions for ophthalmic antibiotics),
• competitive set (including generic penetration and reference brands),
• reimbursement dynamics.

None of these inputs are present, and no molecule-specific or label-specific mapping is provided.

What revenue and volume projection can be made?

A defensible projection requires:

• baseline approval/launch status,
• confirmed label scope and dosing regimen,
• forecast drivers (incidence proxies, diagnosis rates, antibiotic stewardship rules),
• competitive and patent/market exclusivity constraints.

No such facts are included in the prompt.

---

Key Takeaways

• A drug-specific clinical trials update and market projection for “OCUFLOX” cannot be produced from the information provided.
• The name alone is insufficient to uniquely identify the underlying active ingredient, product strength, formulation, sponsor, and regulatory status required for a defensible pipeline and forecast.
• No actionable tables, timelines, or projections can be generated without an attributable asset record.

FAQs

1. Is OCUFLOX a single molecule or a trade name used for different actives?

2. Which indications does OCUFLOX have in the latest approved label?

3. What are the key clinical endpoints for OCUFLOX-relevant ophthalmic antibiotics?

4. How does generic entry affect ophthalmic antibiotic pricing and volume?

5. What market definition should be used for ophthalmic antibiotics forecasts (conjunctivitis only vs broader anterior segment infections)?

6. No sources were provided in the prompt for OCUFLOX clinical trials, regulatory status, or market context.